Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity

Brain and Behavior

Volumn 3, Issue 2, 2013, Pages 67-74

  Lopes, João P ^a   Tarozzo, Glauco ^a   Reggiani, Angelo ^a   Piomelli, Daniele ^a,b   Cavalli, Andrea ^a,c  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Alzheimer's disease; Drug combination; NMDA neurotoxicity; NR2B; Polypharmacology; Primary cortical neurons

Indexed keywords

BUNGAROTOXIN RECEPTOR; DIHYDRO BETA ERYTHROIDINE; GALANTAMINE; IFENPRODIL; MEMANTINE; METHYLLYCACONITINE; N METHYL DEXTRO ASPARTIC ACID; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EXCITOTOXICITY; FEMALE; IC 50; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT;

EID: 84893466236     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.118     Document Type: Article

References (32)

1. Agostinho, P., and C. R. Oliveira, 2003. Involvement of calcineurin in the neurotoxic effects induced by amyloid-beta and prion peptides. Eur. J. Neurosci. 17:1189-1196.
2. Akaike, A., Y. Takada-Takatori, T. Kume, and Y. Izumi, 2010. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J. Mol. Neurosci. 40:211-216.
3. Akasofu, S., M. Kimura, T. Kosasa, H. Ogura, and K. Sawada, 2006. Protective effect of donepezil in primary-cultured rat cortical neurons exposed to N-methyl-d-aspartate (NMDA) toxicity. Eur. J. Pharmacol. 530:215-222.
4. Alzheimer's Disease International. 2009. World Alzheimer Report 2009. Alzheimer's Disease International, Illinois, IL. Available at http://www.alz.co.uk/ (accessed September 2012).
5. Chen, H. S., and S. A. Lipton, 1997. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. 499(Pt 1):27-46.
6. Chen, H. S., and S. A. Lipton, 2006. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 97:1611-1626.
7. Chen, H. S., J. W. Pellegrini, S. K. Aggarwal, S. Z. Lei, S. Warach, F. E. Jensen, et al. 1992. Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12:4427-4436.
8. Citron, M. 2010. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9:387-398.
9. Davies, P., and A. J. Maloney, 1976. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403.
10. Gauthier, S., Y. Wirth, and H. J. Mobius, 2005. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry 20:459-464.
11. Grossberg, G. T., K. R. Edwards, and Q. Zhao, 2006. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. J. Clin. Pharmacol. 46:17S-26S.
12. Kihara, T., H. Sawada, T. Nakamizo, R. Kanki, H. Yamashita, A. Maelicke, et al. 2004. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem. Biophys. Res. Commun. 325:976-982.
13. Lipton, S. A. 2006. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5:160-170.
14. Liu, Y., T. P. Wong, M. Aarts, A. Rooyakkers, L. Liu, T. W. Lai, et al. 2007. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 27:2846-2857.
15. Lorrio, S., M. Sobrado, E. Arias, J. M. Roda, A. G. Garcia, and M. G. Lopez, 2007. Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J. Pharmacol. Exp. Ther. 322:591-599.
16. Maelicke, A., and E. X. Albuquerque, 2000. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur. J. Pharmacol. 393:165-170.
17. Melo, J. B., C. Sousa, P. Garcao, C. R. Oliveira, and P. Agostinho, 2009. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur. J. Neurosci. 29:455-464.
18. Minkeviciene, R., P. Banerjee, and H. Tanila, 2008. Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacology 54:1079-1085.
19. Moriguchi, S., W. Marszalec, X. Zhao, J. Z. Yeh, and T. Narahashi, 2004. Mechanism of action of galantamine on N-methyl-d-aspartate receptors in rat cortical neurons. J. Pharmacol. Exp. Ther. 310:933-942.
20. Peskind, E. R., S. G. Potkin, N. Pomara, B. R. Ott, S. M. Graham, J. T. Olin, et al. 2006. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am. J. Geriatr. Psychiatry 14:704-715.
21. Pieta Dias, C., M. N. Martins De Lima, J. Presti-Torres, A. Dornelles, V. A. Garcia, F. Siciliani Scalco, et al. 2007. Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 146:1719-1725.
22. Samochocki, M., A. Höffle, A. Fehrenbacher, R. Jostock, J. Ludwig, C. Christner, et al. 2003. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 305:1024-1036.
23. Schulz, J. B., M. Rainer, H. H. Klunemann, A. Kurz, S. Wolf, K. Sternberg, et al. 2011. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. J. Alzheimers Dis. 25:463-475.
24. Simoni, E., S. Daniele, G. Bottegoni, D. Pizzirani, M. L. Trincavelli, L. Goldoni, et al. 2012. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J. Med. Chem. 55:9708-9721.
25. Takada, Y., A. Yonezawa, T. Kume, H. Katsuki, S. Kaneko, H. Sugimoto, et al. 2003. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. 306:772-777.
26. Takada-Takatori, Y., T. Kume, M. Sugimoto, H. Katsuki, H. Sugimoto, and A. Akaike, 2006. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51:474-486.
27. Thomas, C. G., A. J. Miller, and G. L. Westbrook, 2006. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J. Neurophysiol. 95:1727-1734.
28. Volbracht, C., J. Van Beek, C. Zhu, K. Blomgren, and M. Leist, 2006. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur. J. Neurosci. 23:2611-2622.
29. White, P., C. R. Hiley, M. J. Goodhardt, L. H. Carrasco, J. P. Keet, I. E. Williams, et al. 1977. Neocortical cholinergic neurons in elderly people. Lancet 1:668-671.
30. Williams, K. 1993. Ifenprodil discriminates subtypes of the N-methyl-d-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol. Pharmacol. 44:851-859.
31. Xia, P., H. S. Chen, D. Zhang, and S. A. Lipton, 2010. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J. Neurosci. 30:11246-11250.
32. Zhao, X., W. Marszalec, P. T. Toth, J. Huang, J. Z. Yeh, and T. Narahashi, 2006. In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology 51:1181-1191.